Cody Simmons
CEO
D
DermaSensor
7/10Traction
DermaSensor provides an FDA Cleared, handheld device that uses optical spectroscopy and proprietary AI algorithms to non-invasively assess suspicious skin lesions. This technology delivers instant risk assessment outputs to aid healthcare providers in making objective referral decisions for melanoma, basal cell carcinoma, and squamous cell carcinoma. The system enhances clinical confidence by offering rapid, objective data to supplement traditional visual assessment at the point of care.
Updated 5 months ago
Funding
Funding not disclosed
Harmonix FundNo round attributed
- harmonixfund.com (opens in a new tab)investor website
Kern Venture GroupNo round attributed
- kernventuregroup.com (opens in a new tab)investor website
Lateral CapitalNo round attributed
- lateralcapital.com (opens in a new tab)investor website
Pier70 VenturesNo round attributed
- pier70ventures.com (opens in a new tab)investor website
Funding rounds are not available yet.
Founders
Product
Problem
Assessing suspicious skin lesions relies heavily on subjective visual interpretation, leading to variability in diagnostic accuracy and referral decisions. This can result in delayed detection of skin cancers or unnecessary referrals, impacting patient outcomes and healthcare resource utilization.
Solution
DermaSensor offers an AI-powered, handheld device that utilizes optical spectroscopy to provide objective data for assessing skin lesions. The FDA-cleared technology analyzes cellular and sub-cellular content by reflecting light off the lesion, processing the data with proprietary algorithms trained on extensive clinical datasets. This enables healthcare providers to make more confident and timely referral decisions at the point of care, improving diagnostic efficiency and patient management for potential skin cancers.
Target Audience
The primary users are healthcare providers across various specialties, including primary care, internal medicine, family medicine, OB/GYN, and medical aesthetics, who evaluate suspicious skin lesions.
Features
- Handheld device employing Elastic Scattering Spectroscopy (ESS) for non-invasive lesion analysis.
- FDA-cleared proprietary AI algorithm trained on over 5,000 diagnosed lesions to assess malignancy risk.
- Provides an immediate output of "Investigate Further" or "Monitor" based on risk level.
- Achieves 96% sensitivity for detecting the three most common skin cancers (Melanoma, Basal Cell Carcinoma, Squamous Cell Carcinoma).
- Integrates a three-step process for lesion assessment, delivering results within 30 seconds.
- Offers cloud storage for device management and on-demand software updates.
- Includes reimbursement guidance and support through a partnership with The Reimbursement Group.